Skip to content

Clinical audit of the long-term use of oral ketamine for management of chronic pain

Long-Term Outcomes From Oral Ketamine Therapy For Treatment Resistant Chronic Pain

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12625000960459
Acronym
N/A
Enrollment
2
Registered
2025-09-02
Start date
2025-07-24
Completion date
2027-07-23
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Oral ketamine has been used for many years as a treatment for chronic pain. Evidence supports the efficacy and relative safety of short to medium term use ( one year) for patients with intractable chronic pain. The aim of this study is to carry out an audit of these patients to assess the safety and efficacy of long-term oral ketamine therapy

Interventions

Questionnaires will be administered: Brief Pain Inventory, Depression and Anxiety Stress Scale, Pain Catastrophizing Scale and Pain Self-efficacy Questionnaire. Patients will also complete a check list of side effects from ketamine treatment. Demographic data will be extracted from Dr Salmons case notes, as well as other analgesia prescribed and patients perception of effects of treatment. Questionnaire responses will be compared with baseline questionnaires (PCS, PSEC, BPI and DASS ) completed

Questionnaires will be administered: Brief Pain Inventory, Depression and Anxiety Stress Scale, Pain Catastrophizing Scale and Pain Self-efficacy Questionnaire. Patients will also complete a check list of side effects from ketamine treatment. Demographic data will be extracted from Dr Salmons case notes, as well as other analgesia prescribed and patients perception of effects of treatment. Questionnaire responses will be compared with baseline questionnaires (PCS, PSEC, BPI and DASS ) completed at initial consultation when the patients first consults with Dr Salmon whenever that appointment occurred. The length of time each patients have been taking will vary, however patients consenting to the study are at least two years post commencement of ketamine therapy. The participating patients are only required to complete one set of questionnaires in addition to the initial (first consultation) questionnaires which is standard care. Patients are approached when attending clinic for follow-up appointments , or contacted by telephone.

Sponsors

Dr John Salmon, PainCare Perth, Parkland House 2/89 Forrest Street Cottesloe WA 6011
Lead SponsorIndividual

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

All patients with treatment resistant severe chronic pain treated by Dr Salmon for at least two years with oral ketamine therapy

Exclusion criteria

Unable to give informed consent. Less than 2 years treatment with ketamine oral medication.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026